Softwr

Healthcare · head to head

Gleamer vs PathAI

Gleamer logo

Gleamer

Healthcare

CE marked and FDA cleared imaging AI suite for bone trauma and chest, now owned by RadNet

From
On request
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Gleamer radNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Gleamer covers BoneView, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Gleamer and PathAI actually diverge.

Attributes where Gleamer and PathAI differ
AttributeGleamerPathAI
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Gleamer

  • BoneView
  • ChestView
  • BoneAge
  • BoneMetrics
  • LungCT and BoneCT
  • BreastView
  • Pixyl.Neuro
  • Gleamer Copilot

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Gleamer

  • An emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident themenot PathAI
  • An urgent care network standardising musculoskeletal reading quality across sites with variable radiology covernot PathAI
  • A paediatric service automating bone age assessment to remove a slow manual atlas comparisonnot PathAI
  • An orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstationnot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Gleamer
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Gleamer
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Gleamer
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Gleamer

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Gleamer

  • RadNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • The measured benefit is largest for less experienced readers, so a specialist musculoskeletal service will see far less improvement than the published reader studies suggest.
  • Cleared indications differ per module and per market, and the FDA cleared set is narrower than the CE marked European set, so an American buyer cannot rely on European reference sites.
  • Each additional module adds alert volume into the same worklist, and departments running several Gleamer algorithms report needing local threshold tuning to keep radiologist trust.
  • Pricing is per exam and not published, which makes budgeting difficult for an emergency department whose plain film volume swings seasonally.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Gleamer

On request
  • Gleamer Copilot$undefined/year
    • Priced per exam analysed or as an annual volume subscription
    • Modules licensed individually or bundled as Copilot
    • Cleared and CE marked indication differs per module and per market

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Gleamer if

  • You need boneview.
  • You work on Web, Cloud, On-premise.
  • You also want chestview.
Gleamer review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Gleamer or PathAI better?
Neither clearly leads. Gleamer starts at On request and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Gleamer or PathAI?
Gleamer starts at On request and PathAI at On request.
Does Gleamer or PathAI run on more platforms?
Gleamer runs on Web, Cloud, On-premise. PathAI runs on Web.
What is Gleamer best used for?
Gleamer is most often used for an emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident theme, an urgent care network standardising musculoskeletal reading quality across sites with variable radiology cover, a paediatric service automating bone age assessment to remove a slow manual atlas comparison, an orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstation. Of those, an emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident theme and an urgent care network standardising musculoskeletal reading quality across sites with variable radiology cover are not what PathAI is typically brought in for.
What can Gleamer do that PathAI cannot?
Gleamer covers BoneView, ChestView, BoneAge, BoneMetrics. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Gleamer: Who owns Gleamer?

RadNet agreed to acquire Gleamer in February 2026 for around two hundred and fifteen million euros upfront. RadNet also owns DeepHealth, a competing AI portfolio.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Gleamer: Is BoneView FDA cleared?

Yes, BoneView holds 510(k) clearance including for paediatric fracture detection, but the cleared finding set is narrower than the CE marked indication in Europe.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Gleamer: What does the evidence actually show?

Multi-reader studies reported improved reader sensitivity for fracture detection and fewer false negatives, with the gain concentrated among less experienced readers in emergency settings.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Gleamer: Can I buy just BoneView?

Yes, modules are licensed individually, though the commercial pitch is now the Copilot bundle across modalities.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Gleamer

More on PathAI

Keep looking

Other head to heads